Sarepta Therapeutics (NASDAQ:SRPT) Given New $175.00 Price Target at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by Cantor Fitzgerald from $231.00 to $175.00 in a research note released on Tuesday, The Fly reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also weighed in on the company. Janney Montgomery Scott cut their target price on Sarepta Therapeutics from $200.00 to $175.00 and set a buy rating on the stock in a research report on Tuesday. ValuEngine lowered Sarepta Therapeutics from a buy rating to a hold rating in a research report on Thursday, August 8th. Zacks Investment Research raised Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 target price on the stock in a research report on Wednesday, May 8th. Robert W. Baird cut their target price on Sarepta Therapeutics from $202.00 to $181.00 and set an outperform rating on the stock in a research report on Tuesday. Finally, Royal Bank of Canada raised their target price on Sarepta Therapeutics from $188.00 to $220.00 and gave the stock an outperform rating in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and twenty-one have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $197.78.

Shares of NASDAQ SRPT opened at $93.61 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.81 and a quick ratio of 7.84. Sarepta Therapeutics has a fifty-two week low of $90.24 and a fifty-two week high of $165.87. The stock’s 50-day simple moving average is $139.42 and its 200-day simple moving average is $130.16.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The business had revenue of $94.67 million for the quarter, compared to analyst estimates of $91.05 million. During the same period last year, the business posted ($1.67) EPS. Sarepta Therapeutics’s revenue was up 28.8% on a year-over-year basis. As a group, research analysts predict that Sarepta Therapeutics will post -4.94 earnings per share for the current fiscal year.

In other news, Director Richard Barry purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average price of $99.32 per share, for a total transaction of $496,600.00. Following the purchase, the director now directly owns 3,182,065 shares of the company’s stock, valued at approximately $316,042,695.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas S. Ingram purchased 16,252 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average price of $123.07 per share, for a total transaction of $2,000,133.64. Following the purchase, the chief executive officer now directly owns 424,405 shares in the company, valued at $52,231,523.35. The disclosure for this purchase can be found here. Insiders have purchased a total of 26,252 shares of company stock worth $3,109,234 in the last 90 days. 6.60% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,232,424 shares of the biotechnology company’s stock valued at $947,017,000 after purchasing an additional 232,752 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Sarepta Therapeutics by 10.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,902,227 shares of the biotechnology company’s stock valued at $592,943,000 after purchasing an additional 359,160 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Sarepta Therapeutics by 2.3% in the 2nd quarter. Janus Henderson Group PLC now owns 2,728,082 shares of the biotechnology company’s stock valued at $414,532,000 after purchasing an additional 62,039 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 14.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 1,255,160 shares of the biotechnology company’s stock valued at $190,722,000 after purchasing an additional 159,225 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC grew its stake in shares of Sarepta Therapeutics by 1.7% in the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 992,371 shares of the biotechnology company’s stock valued at $118,281,000 after purchasing an additional 16,666 shares during the last quarter. Hedge funds and other institutional investors own 93.59% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: Day Trading – Risk Worth the Reward?

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.